Your September e-Newsletter
                                                                          

View in browser [link removed]

( [link removed] )

( [link removed] )
Hi John,

We hope you're keeping well. September often feels like a month of change. For many, sunny skies have made way for cloudy afternoons and whether it's the weather or the return to work and school ( [link removed] ), there's plenty of things shifting and on the move.

In lots of ways, the same can be said within the diabetes world. We've had a month of huge research announcements, including the start of a game-changing new era for ( [link removed] )type 1 diabetes treatment ( [link removed] ), ( [link removed] ) plus draft guidance from NICE that could revolutionise ( [link removed] ) ( [link removed] )treatment for type 2 ( [link removed] ).

And whilst not everyone can spend their days doing incredible things inside a research lab, it doesn't mean that we can't make a difference outside one. We've got a run of autumn events on the horizon that we're excited to share with you, including our series of Wellness Walks ( [link removed] ) and our 62 Miles in October ( [link removed] ) challenge.

All that remains is to say thank you for your continued support. By simply taking the time to read this newsletter, you're staying connected, learning more about our work, and giving us the chance to share the impact your support is making.

And if we had one piece of advice - wrap up warm ( [link removed] ). It's getting colder next week!

( [link removed] )
Walk For Your Wellness

We've got two epic Wellness Walks coming up, with our flagship London Bridges event taking place on Sunday, 28 September and our brand new Manchester route kicking off on Sunday, 19 October. Both days are guaranteed to stick long in your memory as you walk with thousands of other people connected to our cause, take in the city sights, and fundraise for our vital work.

Sign up today ( [link removed] )

( [link removed] )
A huge research breakthrough

The first ever immunotherapy for type 1 diabetes has been licensed for use in the UK. The MHRA has concluded that teplizumab is safe and effective at delaying the development of type 1 diabetes for people in the early stages of the condition. This is an incredible step forward and we'll continue fund world-class research that makes change like this possible.

Find out more ( [link removed] )

P.S. Did you know over 35% of our work is made possible thanks to gifts in Wills? A small gift, once you’ve taken care of loved ones, could spark the research breakthroughs of tomorrow and rewrite the future for the next generation of people affected by diabetes. Find out more today ( [link removed] ).

( [link removed] )
Have a great start to the autumn,
Henry from Diabetes UK
( [link removed] )
( [link removed] )

Let us know how you felt about this email, John

😀 ( [link removed] )

😐 ( [link removed] )

🙁 ( [link removed] )

Follow Diabetes UK

( [link removed] )
( [link removed] )
( [link removed] )
( [link removed] )
( [link removed] )

Get in touch

Contact us ( [link removed] )
Jobs ( [link removed] )

Useful information

About us ( [link removed] )
Helpline ( [link removed] )
Membership ( [link removed] )
Our strategy ( [link removed] )

View our Privacy ( [link removed] ) and Cookies ( [link removed] ) policies.

Diabetes UK is the operating name of the British Diabetic Association, a charity registered in England and Wales (no. 215199) and in Scotland (no. SC039136) A company limited by guarantee. Registered in England and Wales (no. 339181) VAT registration No. 232 3801 96. Registered office: Diabetes UK | 126 Back Church Lane | London E1 1FH | United Kingdom.

If you do not wish to receive further emails from us, please unsubscribe [link removed].